S-1/A: Tempus AI Files for IPO, Aiming to Revolutionize Precision Medicine with AI

Tempus AI, a healthcare technology company, is going public to further its mission of using AI to personalize diagnostics and treatment.

Summary

• Tempus AI, Inc., a healthcare technology company, has filed an amendment to its S-1 registration statement for an initial public offering (IPO).
• The company aims to revolutionize precision medicine by applying artificial intelligence (AI) to diagnostics.
• Tempus's platform integrates technology and healthcare expertise to provide personalized, data-driven therapy selection and development.
• The company is offering 11,100,000 shares of Class A common stock, with an estimated initial public offering price between $35.00 and $37.00 per share.
• Following the offering, Tempus will have two classes of common stock: Class A (one vote per share) and Class B (30 votes per share).
• The CEO will beneficially own approximately 65.3% of the voting power after the offering.
• Tempus has granted the underwriters an option to purchase up to an additional 1,665,000 shares to cover over-allotments.
• The company's Class A common stock has been approved for listing on the Nasdaq Global Select Market under the symbol TEM.
• Tempus is an emerging growth company and will comply with certain reduced reporting requirements.
• The company generated total revenue of $531.8 million in 2023, with a net loss of $214.1 million.
• Adjusted EBITDA for 2023 was $(154.2) million.
• The company's platform includes proprietary software and data pipelines, connecting over 2,000 healthcare institutions.
• Tempus operates robotic sequencing labs in Chicago, Atlanta, and Raleigh.
• The company has three product lines: Genomics, Data and Services, and AI Applications.
• On May 18, 2024, Tempus entered into a Joint Venture Agreement with SoftBank to engage in business activities in Japan.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is growing and has promising technology, it is also incurring significant losses and faces numerous risks. The IPO itself is a positive step, but the concentration of voting power and potential for future stock dilution are concerns.

Positives

• The company's clinical NGS volume in oncology rose from approximately 31,000 samples in 2018 to approximately 288,000 samples in 2023.
• The company has signed contracts with a remaining total contract value of more than $920.0 million, which includes approximately $300.0 million in additional potential future contractual opt-ins.
• The company has a joint venture with SoftBank to expand its business into Japan.
• The company's Cohort Lifetime Value for the 2018 cohort was $48.8 million as of December 31, 2023.
• The company's Cohort Lifetime Value for the 2023 cohort was $182.2 million in its first year of existence.

Negatives

• The company has incurred significant losses since inception, with a net loss of $214.1 million in 2023.
• The company's adjusted EBITDA for 2023 was $(154.2) million.
• The company is an emerging growth company and will comply with certain reduced reporting requirements.

Risks

• The company's current or future products may not achieve or maintain sufficient commercial market acceptance.
• The company's operating results may fluctuate significantly, which makes its future operating results difficult to predict.
• The success of the company's business depends on its continued access to, and ability to monetize, de-identified patient data.
• The company will need to raise additional capital to fund its existing operations, develop its Platform, commercialize new products or expand its operations.
• If third-party payers do not provide coverage of, or adequate reimbursement for, the company's tests, its business will be negatively affected.
• Failure of, or defects in, the company's Platforms AI software could impair its ability to process data, develop products, or provide test results.
• The dual class structure of the company's common stock will concentrate voting control with the CEO.
• The company anticipates incurring substantial federal and state tax withholding and remittance obligations in connection with the settlement of RSUs that vest in connection with this offering.

Future Outlook

Tempus aspires to expand into all major disease areas globally and deploy AI and machine learning capabilities to build algorithmic diagnostics at scale across diseases.

Industry Context

The announcement reflects the growing trend of technology companies entering the healthcare space, particularly in diagnostics and personalized medicine. Tempus is positioning itself to compete with both traditional diagnostic labs and other technology companies by combining expertise in both areas.

Comparison to Industry Standards

• The document mentions competitors such as Foundation Medicine, Caris Life Sciences, Guardant Health, and Flatiron Health.
• Tempus is positioning itself as a company that combines the capabilities of a traditional diagnostics company with those of a technology company.
• The document highlights the company's large multimodal dataset as a key differentiator, suggesting that it is larger and more comprehensive than those of its competitors.
• The document also highlights the company's ability to launch generative AI Applications at scale as a unique differentiator of its Platform.

Legal Proceedings

• On June 11, 2024, Guardant filed a complaint for patent infringement against Tempus AI alleging that certain Tempus products infringe five Guardant U.S. patents.

Related Party Transactions

• Eric Lefkofsky, the CEO, has affiliations with Lightbank LLC and Pathos AI, Inc., which have business relationships with Tempus.
• The company subleases a portion of its office space to Lightbank LLC, Lefkofsky Family Foundation and 346 Investment Partners, each an entity affiliated with and controlled by Mr. Lefkofsky.
• The company charters an aircraft for business use from 346 Investment Partners LLC, an entity affiliated with and controlled by Mr. Lefkofsky.
• The company has a master agreement with Pathos AI, Inc., a company co-founded by Mr. Lefkofsky and Mr. Fukushima, for data licensing and other services.
• The company has a warrant to purchase shares of Pathos AI, Inc.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution in the net tangible book value of the shares of Class A common stock they purchase in this offering.
• The dual class structure of the company's common stock will concentrate voting control with the CEO, which will limit other shareholders' ability to influence important decisions.
• The company's success depends on its ability to attract and retain highly skilled scientists, clinicians, sales representatives and business development managers.
• The company's ability to provide quality technical support and services for its Data and Services products will impact customer satisfaction and retention.
• The company's ability to obtain or maintain adequate reimbursement for its Genomics product line will impact its ability to expand internationally.

Next Steps

• The company will complete the initial public offering.
• The company will continue to develop and commercialize new products and services.
• The company will expand its capabilities and commercial traction outside of oncology.
• The company will expand internationally.

Key Dates

Keywords

Tempus AI, IPO, precision medicine, artificial intelligence, genomics, diagnostics, data and services, AI applications, clinical trials, healthcare, NGS, oncology, SoftBank, Japan, market opportunity